These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 27542970)
21. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625 [TBL] [Abstract][Full Text] [Related]
22. Demethoxycurcumin analogue DMC-BH exhibits potent anticancer effects on orthotopic glioblastomas. Shi L; Sun G; Zhang Y Aging (Albany NY); 2020 Nov; 12(23):23795-23807. PubMed ID: 33221748 [TBL] [Abstract][Full Text] [Related]
23. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515 [TBL] [Abstract][Full Text] [Related]
24. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334 [TBL] [Abstract][Full Text] [Related]
26. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217 [TBL] [Abstract][Full Text] [Related]
27. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782 [TBL] [Abstract][Full Text] [Related]
28. The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H Oncotarget; 2018 Jan; 9(1):706-717. PubMed ID: 29416647 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. Doghman M; Lalli E Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230 [TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354 [TBL] [Abstract][Full Text] [Related]
31. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Kuger S; Flentje M; Djuzenova CS Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922 [TBL] [Abstract][Full Text] [Related]
32. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231 [TBL] [Abstract][Full Text] [Related]
33. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725 [TBL] [Abstract][Full Text] [Related]
34. Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation. Wang Y; Yu Q; He X; Romigh T; Altemus J; Eng C Mol Cancer Ther; 2014 Feb; 13(2):517-27. PubMed ID: 24356815 [TBL] [Abstract][Full Text] [Related]
35. ω3-polyunsaturated fatty acids induce cell death through apoptosis and autophagy in glioblastoma cells: In vitro and in vivo. Kim S; Jing K; Shin S; Jeong S; Han SH; Oh H; Yoo YS; Han J; Jeon YJ; Heo JY; Kweon GR; Park SK; Park JI; Wu T; Lim K Oncol Rep; 2018 Jan; 39(1):239-246. PubMed ID: 29192322 [TBL] [Abstract][Full Text] [Related]
36. Antitumor Efficacy of Liposome-Encapsulated NVP-BEZ235 Combined with Irreversible Electroporation for Head and Neck Cancer. Tian L; Wang L; Qiao Y; Lu L; Lee P; Chang A; Ravi S; Rogers TA; Melancon MP Molecules; 2019 Oct; 24(19):. PubMed ID: 31581445 [TBL] [Abstract][Full Text] [Related]
37. Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation. Gwak HS; Park MJ; Park IC; Woo SH; Jin HO; Rhee CH; Jung HW J Neurosurg; 2014 Dec; 121(6):1483-91. PubMed ID: 25303017 [TBL] [Abstract][Full Text] [Related]
39. Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling. Atif F; Yousuf S; Stein DG J Steroid Biochem Mol Biol; 2015 Feb; 146():62-73. PubMed ID: 24787660 [TBL] [Abstract][Full Text] [Related]
40. Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagy. Zhang LD; Liu Z; Liu H; Ran DM; Guo JH; Jiang B; Wu YL; Gao FH Int J Oncol; 2016 Aug; 49(2):657-65. PubMed ID: 27278249 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]